Synthetic Peptide Gelation for Surgical Bleeding Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing surgical procedures face challenges with excessive bleeding, which can be dangerous and life-threatening, and current methods using animal-derived products pose risks of infection and immune responses.

Innovation Solution

A peptide solution with an amino acid sequence of n-RADARADARADARADA is used to transition between ungelled and gelled states in response to ion presence, effectively controlling bleeding during surgeries by applying it to surgical sites, optionally with an anticoagulant.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If animal-derived products are used for bleeding control, then effectiveness is achieved, but risks of infection and immune responses increase

Engineering Contradiction:
Improvebleeding control effectivenessVSAvoidinfection and immune response risks
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs synthetic peptide compositions that are chemically synthesized rather than animal-derived, eliminating the risks of infection and immune responses associated with animal products. These synthetic peptides are designed to be biodegradable and are administered in controlled amounts during surgical procedures.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent utilizes peptides that undergo conformational changes in response to physiological conditions (such as pH and ion concentration) to transition from a soluble state to a gelated state at the bleeding site. This parameter change enables the peptides to effectively control bleeding while maintaining safety and biocompatibility.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If standard bleeding control methods are used, then bleeding is managed, but surgical time increases

Engineering Contradiction:
Improvebleeding controlVSAvoidsurgical procedure duration
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The synthetic peptide compositions are pre-formulated in a soluble state for easy administration during surgery. Upon application to the bleeding site, they rapidly transition to a gelated state, providing immediate bleeding control without requiring complex preparation or multiple steps, thus reducing surgical time.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent exploits phase transitions of the peptide compositions from soluble to gelated state in response to physiological conditions at the bleeding site. This rapid phase transition provides quick and effective bleeding control, eliminating the need for time-consuming standard bleeding control procedures.

Inventive Principle:
Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide solution reduces bleeding, shortens surgical times, and eliminates risks associated with animal-derived products, providing a safer and more effective bleeding control method.

Implementation Method 1

the solution is characterized by an ability to transition between two states: an ungelled state adopted when one or more particular ions is substantially absent, and a gelled state adopted when the one or more ions is present at or above a threshold level

Methodology Applied
Scientific EffectGelation: Gel

Data Source

PatentEP3777875B1Surgical methods employing purified amphiphilic peptide compositions
Publication Date: 2025.12.03 3D-MATRIX LTD
  • EP3777875B1 patent drawingFigure 1
  • EP3777875B1 patent drawingFigure 2
  • EP3777875B1 patent drawingFigure 3

AI summary

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).